Intranasal vaccination: A potent one-time solution for comprehensive COVID-19 immunity

A single-dose intranasal vaccine effectively induces robust immune responses.

Routine lab tests fail to detect long COVID in 10,000-person study

Dive Brief: A study of more than 10,000 people found no evidence that any of 25 routine laboratory tests can detect long COVID. The study,

August 16, 2024

Existing drug alleviates symptoms of a rare genetic syndrome

A drug approved to treat certain autoimmune diseases and cancers successfully alleviated symptoms of a rare genetic syndrome called autoimmune polyendocrine syndrome type 1 (APS-1).

May 30, 2024

PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine) – Psychedelic Alpha

FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher’s commitment toward unlocking the potential of ketamine for unmet medical needs TORONTO,

September 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.